ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2146

Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease

Emily Carroll1, Amanda Leiter 2, Danielle Brooks 1, Jennifer Ben Shimol 3, Elliot Eisenberg 1, Matthew Galsky 4, Emily Gallagher 5 and Margrit Wiesendanger 3, 1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 2Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 3Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 4Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, 5Division of Endocrinology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: adverse events and cancer treatments, Immunotherapy

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies in the treatment of many cancers, but their use has been linked with immune-related adverse events (irAEs). As use of ICIs becomes more widespread, more patients are developing irAEs including rheumatologic manifestations. Thus, it is important that clinicians monitor for irAEs and identify patients who may be at increased risk for developing them. We sought to describe the prevalence and presentation of irAEs, both in general and specifically rheumatologic, in order to better characterize their clinical manifestations and recognize potential predisposing risk factors. We hypothesized that patients with preexisting rheumatologic disease would experience irAEs at an increased rate compared to those without preexisting conditions.

Methods: We performed an IRB approved retrospective review using an EMR database of patients treated with ICIs at our institution from January 2011 to April 2017. We reviewed charts to assess for the presence of preexisting rheumatologic disease as well as the development of irAEs during ICI treatment. In patients who experienced an irAE, we determined whether they required additional work up, glucocorticoid treatment, hospitalization, or cessation of ICI therapy. To see if there was an association between preexisting rheumatologic disease and developing irAEs, we did comparative analysis using the Fisher exact test. 

Results: Of 420 patients treated with ICIs, 4.8% (n=20) experienced rheumatologic irAEs. As a result, 4 were referred for rheumatology consultation, 7 were treated with glucocorticoids, 3 had to delay or stop ICIs, and 0 required hospitalization. Preexisting rheumatologic disease was present in 4.8% (n=20). In this subgroup, 65% (n=13) developed any irAE compared to 43% (n=172) of those without preexisting rheumatologic disease (p=0.065). 15% (n=3) developed a rheumatologic irAE compared to 4.25% (n=17) of those without preexisting rheumatologic disease (p=0.063).

Conclusion: We did not detect a statistically significant difference in the rates of irAEs in patients with preexisting rheumatologic disease; however, this study was limited by its retrospective design and relatively small sample size. Given that p-values neared significance, it is possible that this study was underpowered to detect a true relationship and thus additional, larger studies would be beneficial to further investigate. Overall, the majority of rheumatologic irAEs did not require treatment or lead to cessation of ICI therapy. This suggests that even if there is found to be a significant relationship between preexisting rheumatologic disease and the development of irAEs, this risk factor should not preclude this population from receiving ICI therapy but would require careful monitoring and collaboration between these patients’ oncologists and rheumatologists.


Disclosure: E. Carroll, None; A. Leiter, None; D. Brooks, None; J. Ben Shimol, None; E. Eisenberg, None; M. Galsky, None; E. Gallagher, Novartis, 5; M. Wiesendanger, None.

To cite this abstract in AMA style:

Carroll E, Leiter A, Brooks D, Ben Shimol J, Eisenberg E, Galsky M, Gallagher E, Wiesendanger M. Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/complications-of-immune-checkpoint-inhibitor-therapy-in-patients-with-and-without-pre-existing-rheumatologic-disease/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complications-of-immune-checkpoint-inhibitor-therapy-in-patients-with-and-without-pre-existing-rheumatologic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.